+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term graft survival with or without donor-specific transfusion in cyclosporine era in one haplo-identical living-related renal transplant recipients beyond the first year: a 19-year experience



Long-term graft survival with or without donor-specific transfusion in cyclosporine era in one haplo-identical living-related renal transplant recipients beyond the first year: a 19-year experience



Tohoku Journal of Experimental Medicine 197(4): 201-207



With improvement in immunosuppressive drugs, the beneficial role of donor-specific blood transfusion (DST) in the preconditioning of renal allograft recipients has been diminished. This retrospective study was conducted to investigate the influence of DST on long-term graft survival in successful one haplotype-mismatched kidney transplantation in the cyclosporine (CsA) era at Iwate Medical University. Between August 1983 and October 1996, 52 one haplotype-mismatched living related first renal transplants were performed. Fifty grafts survived beyond the first year after transplantation. These 50 patients were divided into two groups according to maintenance immunosuppression, 12 kidney graft recipients received azathioprine (AZA), prednisolone (PSL), CsA, and DST, and 38 recipients received AZA, PSL and CsA. Our DST protocol consisted of three transfusions of 30 ml of donor-specific buffy-coat at 4-week intervals, without immunosuppressive coverage. In recipients receiving DST and CsA, the 5-, 10-, and 13-year graft survival rates were 100%, 83%, and 67%, respectively. In recipients without DST, the 5-, 10-, and 13-year graft survival rates were 95%, 74%, and 69%, respectively. There was no significant difference between the two groups in long-term graft survival. In conclusion, DST and CsA combination treatment in our protocol may not induce long standing donor-specific immunologic hyporesponsiveness. Other strategies are expected to induce immunotolerance.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010935696

Download citation: RISBibTeXText

PMID: 12434995

DOI: 10.1620/tjem.197.201


Related references

Role of preoperative donor-specific transfusion and cyclosporine in haplo-identical living related renal transplant recipients. Nephron 75(1): 20-24, 1997

Role of Preoperative Donor-Specific Transfusion and Cyclosporine in Haplo-ldentical Living Related Renal Transplant Recipients. Nephron 75(1): 20-24, 1997

Prophylactic use of deoxyspergualin improves long-term graft survival in living related renal transplant recipients transfused with donor-specific blood. Transplantation Proceedings 33(3): 2256-2257, 2001

Deoxyspergualin prophylaxis with tacrolimus further improves long-term graft survival in living-related renal-transplant recipients transfused with donor-specific blood. Transplantation Proceedings 37(2): 927-929, 2005

Evaluation of pre- and posttransplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Transplantation 68(8): 1117-1124, 1999

Donor specific transfusions for haplo identical living related renal transplants using cyclosporine pretreatment. Transplantation Proceedings 18(4): 695-698, 1986

Long-term follow-up of living donor renal transplant recipients sensitized after donor specific blood transfusion. Transplantation Proceedings 33(1-2): 1221-1223, 2001

Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience. Clinical and Experimental Nephrology 11(2): 151-155, 2007

Evaluation of pre- and posttransplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Cooperative Clinical Trials in Transplantation Research Group. Transplantation 68(8): 1117-1124, 1999

A prospective clinical trial of cyclosporine and donor specific transfusion vs donor specific transfusion alone in living related renal allograft recipients. Transplantation Proceedingspart 2: 1242-1243, 1985

Long term follow-up in recipients of HLA identical living related donor kidney recipients receiving continuous cyclosporine. Clinical & Investigative Medicine 19(4 Suppl. ): S98, 1996

Donor specific blood transfusion and renal graft survival a 3 year experience in pediatrics. Albert, E D , M P Baur And W R Mayr (Ed ) Histocompatability Testing ; 9th International Workshop And Conference, Munich, West Germany, May 6-11, ; Vienna, Austria, May 13-15, Xxvii+764p Springer-Verlag: New York, N Y , Usa; Berlin, West Germany Illus 669-670, 1984

Long-term graft survival of living-related kidneys after donor-specific transfusion. Transplantation Proceedings 32(7): 1741-1742, 2000

The effect of pretransplant stored donor-specific blood transfusion on renal allograft survival in one-haplotype living-related transplant recipients. Transplantation 38(6): 654-656, 1984

Donor-specific blood transfusion in living-related renal transplantation: fourteen-year experience. Transplantation Proceedings 29(1-2): 200-202, 1997